Abstract
Indonesia remains one of the poorest countries in South East Asia and lags
behind in many areas of healthcare provision. This report is ideal for
executives wanting to understand the key drivers in the pharmaceutical market
and have access to a wealth of statistical data, including five-year market
projections. Included with the report are 3 free quarterly updated outlook
reports, enabling you to keep up to date with market developments for a year.
Includes 3 quarterly updated outlook reports!
The Indonesian market remains characterised by its complexity and
competitiveness. Pharmaceuticals imported in finished form play only a small
role in the market, being restricted to supplies of highly advanced products.
Most requirements are locally manufactured using imported raw materials.
Prior to 1997, only Indonesian-owned companies were allowed to undertake
import/export activities, wholesaling or retailing. This situation was
liberalised at the behest of the IMF. In November 1997, overseas companies
were allowed to engage in wholesaling activities, provided they first obtain a
licence. In 1998, this relaxation was extended to the retailing of goods by
foreign companies. It should be noted, however, that foreign companies are not
allowed to both distribute and retail their products. Restrictions on the
import/export of products still apply.
Indonesia' s trade policies have become increasingly liberal in recent years, a
move accelerated by the prescriptions of the IMF following the 1997 economic
collapse. Tariffs have been reduced several times since 1996, and the whole
tariff structure has been simplified. The system remains relatively costly and
complex, however. Other major considerations include Indonesia' s tax regime,
which is complex despite reform, and the legal system, derived from Dutch
colonial law.
In recent years, approval delays and the confidentiality of dossier data have
been the main concerns of pharmaceutical multinationals operating in
Indonesia. It is hoped that the latest restructuring of the drug regulatory
system will address these concerns.
MARKET OUTLOOK
- Current market size
- Unique 5-year market projections
- Market outlook
- Market structure
- Includes data on imports and exports for raw materials and finished
products
- Market developments
- Recent and impending developments with respect to key issues such as
regulation, health facilities and government policy
- Key national data projections
BACKGROUND DATA
- Population data, including growth trends and age structure
- Demographic indicators detailing principal causes of death and morbidity
HEALTHCARE SYSTEM
- Health expenditure
- Hospital services
- Hospital data such as beds by region and sector
- Outpatient care
- Medical personnel
- Data on healthcare professionals covering such areas as doctors by
specialty, nursing staff and dentists
ACCESSING THE PHARMACEUTICAL MARKET
- Regulatory environment
- Patent protection & intellectual property rights
- Distribution channels
- Domestic production
CONTACT DETAILS
For healthcare organisations and trade associations.
Compelling reasons to buy this Espicom market report
Espicom is a leading provider of market and company information for business.
In addition to this analysis, Espicom provides detailed management reports on
over 60 established and emerging pharmaceutical markets around the world.
- Includes - FREE - three quarterly updated outlook reports on
Indonesia' s pharma market
- Unique and original market forecasts
- Insightful interpretation of market trends and developments
- Fantastic value - no-one else produces such quality data so cost
effectively
- Over 25 years continuous pharmaceutical market experience
- A team of full-time researchers and analysts
- Unbeatable access to primary sources
- Independent and impartial
- Formats to suit every distribution need and budget
View Cart
